JP2012511305A - 癌の治療および診断の標的遺伝子としてのネクチン−４ - Google Patents

癌の治療および診断の標的遺伝子としてのネクチン−４ Download PDF

Info

Publication number
JP2012511305A
JP2012511305A JP2011525307A JP2011525307A JP2012511305A JP 2012511305 A JP2012511305 A JP 2012511305A JP 2011525307 A JP2011525307 A JP 2011525307A JP 2011525307 A JP2011525307 A JP 2011525307A JP 2012511305 A JP2012511305 A JP 2012511305A
Authority
JP
Japan
Prior art keywords
nectin
cancer
double
level
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011525307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012511305A5 (https=
Inventor
祐輔 中村
弥太郎 醍醐
卓也 角田
義朗 岸
慶宏 藤井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JP2012511305A publication Critical patent/JP2012511305A/ja
Publication of JP2012511305A5 publication Critical patent/JP2012511305A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57565—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen [CEA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
JP2011525307A 2008-12-12 2009-08-21 癌の治療および診断の標的遺伝子としてのネクチン−４ Withdrawn JP2012511305A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20181108P 2008-12-12 2008-12-12
US61/201,811 2008-12-12
PCT/JP2009/004026 WO2010067487A1 (en) 2008-12-12 2009-08-21 Nectin-4 for target genes of cancer therapy and diagnosis

Publications (2)

Publication Number Publication Date
JP2012511305A true JP2012511305A (ja) 2012-05-24
JP2012511305A5 JP2012511305A5 (https=) 2012-10-11

Family

ID=42242486

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011525307A Withdrawn JP2012511305A (ja) 2008-12-12 2009-08-21 癌の治療および診断の標的遺伝子としてのネクチン−４

Country Status (4)

Country Link
US (1) US20110301056A1 (https=)
EP (1) EP2373794A4 (https=)
JP (1) JP2012511305A (https=)
WO (1) WO2010067487A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020510432A (ja) * 2017-03-02 2020-04-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｎｅｃｔｉｎ−４への特異性を有する抗体及びその使用
JP2020533311A (ja) * 2017-09-07 2020-11-19 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2517555A4 (en) 2009-12-25 2014-09-24 Chugai Pharmaceutical Co Ltd SEARCHING AND SCREENING METHOD FOR A TARGET MOLECULE OF A CANCER WITH A NON-MENTAL ANIMAL MODEL WITH A NO-CANCER LINE OF TRANSPLANTED LINE
JP6230789B2 (ja) 2010-10-06 2017-11-15 中外製薬株式会社 癌幹細胞集団及びその作製方法
CA2825094C (en) * 2011-01-18 2020-01-07 Dalhousie University Pvrl4 (nectin 4) is a receptor for measles virus.
EP2772268B8 (en) 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
EP3347048B1 (en) * 2015-09-09 2020-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
WO2018226578A1 (en) 2017-06-05 2018-12-13 Agensys, Inc. Nectin-4-binding proteins and methods of use thereof
US12123881B2 (en) * 2018-04-20 2024-10-22 Unm Rainforest Innovations Rap1-Gtp, Rac1-GTP and FMS-like tyrosine kinase 3 ligand (FLT3-L) as biomarkers for early detection of sepsis
KR102280672B1 (ko) * 2019-12-20 2021-07-23 주식회사 베르티스 암의 진단용 조성물
EP4096717B1 (en) 2020-01-31 2024-12-11 Innate Pharma Treatment of cancer
JP7735291B2 (ja) * 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
CN115768798A (zh) * 2020-06-18 2023-03-07 生物蛋白有限公司 条件活性抗粘附分子-4(nectin-4)抗体
MX2023005873A (es) * 2020-11-25 2023-06-05 Innate Pharma Tratamiento del cancer.
WO2022253051A1 (zh) * 2021-06-01 2022-12-08 南京明德新药研发有限公司 多肽偶联药物及其应用
AU2023273063A1 (en) * 2022-05-16 2024-11-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition containing anti-nectin-4 antibody drug conjugate and use thereof
CA3262070A1 (en) * 2022-07-14 2025-06-13 Bio-Thera Solutions, Ltd. ANTI-NECTIN-4 ANTIBODIES AND THEIR USES
CN115877008A (zh) * 2022-12-05 2023-03-31 中国科学院自动化研究所 用于膀胱癌检测的光学分子成像探针及其制备方法和应用
WO2024251260A1 (zh) * 2023-06-08 2024-12-12 江苏迈威康新药研发有限公司 结合Nectin-4的抗体及其用途
CN120271712A (zh) * 2025-04-18 2025-07-08 哈尔滨医科大学 靶向Nectin-4的纳米抗体及其应用
CN120330199B (zh) * 2025-06-23 2025-08-29 上海交通大学医学院附属仁济医院 一种Nectin-4靶向核酸适体核素诊疗一体化探针

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20080268476A1 (en) * 2004-05-12 2008-10-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nectin 4 (N4) as a Marker for Cancer Prognosis
US20090214517A1 (en) * 2004-07-27 2009-08-27 Justin Wong Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
CN101175862A (zh) * 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020510432A (ja) * 2017-03-02 2020-04-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｎｅｃｔｉｎ−４への特異性を有する抗体及びその使用
JP2020533311A (ja) * 2017-09-07 2020-11-19 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質
JP7431392B2 (ja) 2017-09-07 2024-02-15 ドラゴンフライ セラピューティクス， インコーポレイテッド ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質

Also Published As

Publication number Publication date
EP2373794A4 (en) 2012-09-05
EP2373794A1 (en) 2011-10-12
WO2010067487A1 (en) 2010-06-17
US20110301056A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
JP2012511305A (ja) 癌の治療および診断の標的遺伝子としてのネクチン−４
US20110152345A1 (en) Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
WO2011096210A1 (en) Prmt1 and prmt6 for target genes of cancer therapy and diagnosis
JP2010536367A (ja) 癌関連遺伝子、ｃｄｃａ５、ｅｐｈａ７、ｓｔｋ３１及びｗｄｈｄ１
JP2012501167A (ja) 膵臓癌関連遺伝子ｔｔｌｌ４
WO2012090479A1 (en) Mcm7 as a target gene for cancer therapy and diagnosis
US20110262463A1 (en) Syngr4 for target genes of cancer therapy and diagnosis
US20120010266A1 (en) Tbc1d7 as tumor marker and therapeutic target for cancer
WO2012023290A1 (en) Rasef as tumor marker and therapeutic target for cancer
WO2012153492A1 (en) Nptx2 as tumor marker and therapeutic target for cancer
US20110160288A1 (en) Oip5 as a target gene for cancer therapy and diagnosis
JP2012501166A (ja) 乳癌関連遺伝子ｒｑｃｄ１
WO2011024433A1 (en) Lung and esophageal cancer related gene adamts18
WO2012023284A1 (en) Lhx4 as a target gene for cancer therapy and diagnosis
WO2011021386A1 (en) Cstf2 for target genes of lung cancer therapy and diagnosis
WO2011018898A1 (en) Cdc45l as tumor marker and therapeutic target for cancer
JP2013502901A (ja) がんの治療および診断の標的遺伝子としてのｅｒｃｃ６ｌ
JP2013502202A (ja) 乳癌関連遺伝子Ｃ１２ｏｒｆ３２

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120820

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130521